Laboratory Corporation of America (LH) Earns News Sentiment Score of 0.19
Media stories about Laboratory Corporation of America (NYSE:LH) have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Laboratory Corporation of America earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.6110653428089 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
A number of research analysts have weighed in on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $170.00 price target (up previously from $157.00) on shares of Laboratory Corporation of America in a research note on Wednesday, September 13th. ValuEngine raised shares of Laboratory Corporation of America from a “hold” rating to a “buy” rating in a research report on Wednesday, September 6th. Mizuho set a $165.00 price objective on shares of Laboratory Corporation of America and gave the stock a “neutral” rating in a research report on Friday, December 1st. Canaccord Genuity reissued a “buy” rating and issued a $180.00 price objective (up previously from $175.00) on shares of Laboratory Corporation of America in a research report on Monday, September 11th. Finally, Morgan Stanley boosted their price objective on shares of Laboratory Corporation of America from $154.00 to $166.00 and gave the stock an “overweight” rating in a research report on Thursday, August 10th. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $170.92.
Laboratory Corporation of America (NYSE LH) traded up $0.29 during trading hours on Wednesday, hitting $155.51. 619,618 shares of the company’s stock traded hands, compared to its average volume of 722,594. Laboratory Corporation of America has a 12-month low of $123.41 and a 12-month high of $164.22. The firm has a market capitalization of $16,075.24, a P/E ratio of 16.98, a P/E/G ratio of 1.68 and a beta of 0.87. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.75 and a current ratio of 1.89.
Laboratory Corporation of America (NYSE:LH) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.38 by $0.08. Laboratory Corporation of America had a net margin of 7.40% and a return on equity of 16.75%. The business had revenue of $2.60 billion for the quarter, compared to the consensus estimate of $2.55 billion. During the same period in the prior year, the company posted $2.25 earnings per share. Laboratory Corporation of America’s revenue was up 9.5% compared to the same quarter last year. equities research analysts expect that Laboratory Corporation of America will post 9.52 earnings per share for the current year.
In related news, Director Dwight Gary Gilliland sold 971 shares of the company’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $153.52, for a total value of $149,067.92. Following the transaction, the director now directly owns 3,501 shares in the company, valued at $537,473.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.90% of the company’s stock.
About Laboratory Corporation of America
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.